Eltrombopag 13C4
| Product Name | Eltrombopag 13C4 |
|---|---|
| Alternate Names | Eltrombopag Stable Isotopes, Stable Isotopes of Eltrombopag |
| CAT No. | CS-O-06578 |
| CAS No. | 496775-61-2(Unlabeled) |
| Category | Stable Isotopes |
| Stock | IN-Stock |
| Mol. Wt. | 446.44 g/mol |
| Mol. For. | C₂₁¹³C₄H₂₂N₄O₄ |
| Hazardous | This is a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Eltrombopag |
| Purity | 95% |
| Therapeutic | Anti-Cancer / Oncology |
| Smileys | O=[13C]1N(C2=CC(C)=C(C)C=C2)N=[13C]([13CH3])/[13C]1=N/NC(C=CC=C3C4=CC(C(O)=O)=CC=C4)=C3O |
| Canonical Smiles | CC1=C(C=C(C=C1)N2C(=O)C(=C(N2)C)N=NC3=CC=CC(=C3O)C4=CC(=CC=C4)C(=O)O)C |
| InchIKey | SVOQIEJWJCQGDQ-UHFFFAOYSA-N |
| Inchl | InChI=1S/C25H22N4O4/c1-14-10-11-19(12-15(14)2)29-24(31)22(16(3)28-29)27-26-21-9-5-8-20(23(21)30)17-6-4-7-18(13-17)25(32)33/h4-13,28,30H,1-3H3,(H,32,33) |
| IUPAC | 3-[3-[[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-1H-pyrazol-4-yl]diazenyl]-2-hydroxyphenyl]benzoic acid |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Eltrombopag 13C4 is a medication that is used to treat a low platelet count in individuals with chronic immune thrombocytopenia (ITP) and hepatitis C virus (HCV) infection. It is a small molecule thrombopoietin (TPO) receptor agonist that works by stimulating the production of platelets in the bone marrow.
Chemically, Eltrombopag 13C4 is represented as C25H22N4O4S with a molecular weight of 442.53 g/mol. It belongs to the class of organic compounds known as quinolines and is structurally similar to endogenous TPO. The drug is administered orally as a tablet and is rapidly absorbed into the bloodstream, with peak plasma concentrations reached within 2 to 6 hours.
Eltrombopag 13C4 is metabolized by the liver and excreted primarily in the feces. It has a half-life of approximately 26 hours, allowing for once-daily dosing. The recommended starting dose for ITP is 50 mg once daily, with adjustments made based on platelet counts. For HCV-associated thrombocytopenia, the recommended dose is 25 mg once daily.
While Eltrombopag 13C4 is generally well-tolerated, it can cause side effects such as headache, nausea, diarrhea, and elevated liver enzymes. It is important for individuals taking this medication to regularly monitor their platelet counts and liver function. Overall, Eltrombopag 13C4 is a valuable treatment option for those with chronic immune thrombocytopenia and HCV-associated thrombocytopenia, helping to increase platelet production and improve overall health.
Get an Instant Quote
Related Compounds
Eltrombopag-14C | Eltrombopag D3 | Eltrombopag D9 |